Metadon Viatris (Methadone Hydrochloride)

Methadone is a full agonist at the mu‑opioid receptor, producing analgesia and reducing cravings. It also blocks NMDA receptors and inhibits the reuptake of serotonin and norepinephrine, which helps alleviate withdrawal symptoms and provides long‑lasting pain relief.

The dose of Metadon Viatris is individualized. A qualified prescriber determines the appropriate amount based on the patient’s clinical condition, prior opioid exposure, and response to therapy, and adjusts it as needed during treatment.

Methadone is classified as Pregnancy Category C, meaning risk cannot be ruled out. It may be used if the potential benefit justifies the risk. Breastfeeding is possible, but infants should be monitored for sedation and respiratory depression, and decisions should be made with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for opioid dependence is buprenorphine, a partial mu‑opioid agonist. Methadone provides full receptor activation and a longer half‑life, which can be advantageous for stable maintenance but carries higher risk of respiratory depression and cardiac effects compared with buprenorphine.

Metadon Viatris should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain potency and sterility.

The medication is supplied as an injectable solution and is administered by a healthcare professional via intramuscular or subcutaneous injection, typically in a clinical setting where dosing can be accurately measured and monitored.

The most critical risks include respiratory depression, especially when combined with other depressants, QT interval prolongation that may lead to arrhythmias, severe hypotension, and the potential for overdose. Patients should be closely monitored during initiation and dose adjustments.

Metadon Viatris is contraindicated in individuals with known hypersensitivity to methadone, severe respiratory depression, acute asthma attacks, or uncontrolled severe cardiac disease. Caution is also advised for patients with significant hepatic impairment or those taking interacting medications.